Healthcare operations

Ascentage Pharma appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, strengthening its leadership team.

• This Info Team
• August 3, 2026

A new prototype allows AA and NA sponsors to conduct anonymous daily check-ins with sponsees via pseudonymous threads, aiming to improve support while maintaining anonymity.

• Thorsten Meyer
• August 1, 2026

The Stork Foundation for Infertility has announced the opening of its 2026 grant applications to help reduce the financial burden of IVF treatments.

• This Info Team
• August 1, 2026

Clearmind Medicine has successfully completed Part A of its FDA-regulated Phase I/II trial, advancing its research into novel therapies.

• This Info Team
• July 28, 2026

New CRISPR technology has demonstrated the ability to selectively destroy resistant cancer cells, including ‘undruggable’ types, marking a significant step in cancer therapy.

• Thorsten Meyer
• July 24, 2026

TransMedics will release its second quarter 2026 financial results on August 4, 2026, with analysts and investors awaiting the report’s details on company performance.

• This Info Team
• July 22, 2026

MaxCyte announces a multi-platform technology licensing partnership with Genentech to accelerate cell therapy development, expanding collaborative capabilities.

• This Info Team
• July 21, 2026

South Korea’s regulatory agency retains conditional approval for Neuronata-R, a key development for its market access and future commercialization.

• This Info Team
• July 20, 2026

A new pilot program tests daily postpartum check-ins for first-time mothers at home, aiming to improve recovery and reduce risks after birth.

• Thorsten Meyer
• July 19, 2026

4DMT announced positive two-year data from its PRISM Phase 2b clinical trial in a broad wet AMD population, showing promising efficacy results.

• This Info Team
• July 19, 2026